News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
240,588 Results
Type
Article (15991)
Company Profile (24)
Press Release (224573)
Section
Business (64304)
Career Advice (641)
Deals (10586)
Drug Delivery (36)
Drug Development (41369)
Employer Resources (36)
FDA (6849)
Job Trends (5539)
News (122850)
Policy (11990)
Tag
Academia (1483)
Alliances (14405)
Alzheimer's disease (894)
Approvals (6862)
Artificial intelligence (64)
Bankruptcy (116)
Best Places to Work (5007)
Breast cancer (104)
Cancer (784)
Cardiovascular disease (88)
Career advice (525)
Cell therapy (153)
Clinical research (33240)
Collaboration (229)
Compensation (125)
COVID-19 (992)
Data (996)
Diabetes (115)
Diagnostics (2330)
Duchenne muscular dystrophy (65)
Earnings (29288)
Events (35491)
Executive appointments (179)
FDA (7307)
Funding (213)
Gene therapy (175)
GLP-1 (326)
Government (1986)
Healthcare (7913)
Infectious disease (1049)
Interviews (85)
IPO (5639)
Job creations (766)
Job search strategy (481)
Layoffs (125)
Legal (1986)
Lung cancer (123)
Lymphoma (63)
Manufacturing (63)
MASH (57)
Medical device (4734)
Medtech (4735)
Mergers & acquisitions (5058)
Metabolic disorders (312)
Neuroscience (1108)
NextGen: Class of 2025 (2342)
Non-profit (1998)
Northern California (971)
Obesity (155)
Opinion (70)
Parkinson's disease (56)
Patents (58)
People (17714)
Phase I (9737)
Phase II (14959)
Phase III (11301)
Pipeline (386)
Postmarket research (1418)
Preclinical (4609)
Radiopharmaceuticals (110)
Rare diseases (173)
Real estate (1061)
Regulatory (8835)
Research institute (1044)
Resumes & cover letters (104)
Southern California (821)
Startups (1064)
United States (7649)
Vaccines (212)
Weight loss (85)
Date
Today (29)
Last 7 days (242)
Last 30 days (1094)
Last 365 days (15133)
2025 (1778)
2024 (15329)
2023 (17167)
2022 (20651)
2021 (22250)
2020 (20997)
2019 (17640)
2018 (13290)
2017 (12434)
2016 (11449)
2015 (13839)
2014 (9521)
2013 (7262)
2012 (7902)
2011 (8129)
2010 (7253)
Location
Africa (223)
Asia (11573)
Australia (2418)
California (2092)
Canada (671)
China (146)
Colorado (83)
Connecticut (82)
Europe (30256)
Florida (254)
Georgia (74)
Illinois (173)
Indiana (109)
Japan (63)
Kansas (54)
Maryland (273)
Massachusetts (1420)
Michigan (63)
Minnesota (97)
New Jersey (667)
New York (638)
North Carolina (331)
Northern California (971)
Ohio (72)
Pennsylvania (447)
South America (316)
Southern California (821)
Texas (277)
Utah (62)
Washington State (237)
240,588 Results for "muscular dystrophy association".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
February 18, 2025
·
6 min read
Policy
Muscular Dystrophy Association Applauds Expanded US FDA Approval of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy Patients Ages 4 and Above
The Muscular Dystrophy Association celebrates the U.S. Food and Drug Administration’s expanded approval of ELEVIDYS.
June 20, 2024
·
5 min read
Duchenne muscular dystrophy
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several companies including Wave, Dyne and Avidity are looking to answer the call with investigational therapies targeting greater efficacy and broader reach.
January 27, 2025
·
8 min read
·
Kate Goodwin
Press Releases
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 21, 2025
·
9 min read
Pharm Country
Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy
The Muscular Dystrophy Association’s funding of foundational research leads to new drug approval by the US Food and Drug Administration (FDA) of Duvyzat (givinostat), a histone deacetylase (HDAC) inhibitor to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
March 21, 2024
·
5 min read
Press Releases
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
February 17, 2025
·
6 min read
Press Releases
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
February 13, 2025
·
5 min read
FDA
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
October 26, 2023
·
6 min read
Press Releases
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
January 16, 2025
·
4 min read
Drug Development
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy
Constant Therapeutics LLC today announced that the first patient was dosed March 3, 2024, in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for Duchenne Muscular Dystrophy-associated (DMD-associated) Cardiomyopathy.
March 4, 2024
·
2 min read
1 of 24,059
Next
